Recruiting Phase 3

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

AbbVie is recruiting participants for a Phase 3 clinical trial evaluating surabgene lomparvovec (ABBV-RGX-314), an investigational gene therapy for neovascular age-related macular degeneration (wet AMD).

The study will evaluate the therapy’s safety and effectiveness, injection burden, disease activity, and long-term preservation of visual acuity.

📌 Learn more about eligibility and study locations:
Visit ClinicalTrials.gov and search NCT07007065.

📞 Study Contact: 844-663-3742
📧 Email: abbvieclinicaltrials@abbvie.com

Surabgene lomparvovec is investigational and has not been established as a safe and effective treatment for wet AMD.

#MacularDegeneration #WetAMD #ClinicalTrials #EyeHealth #VisionResearch

The post Clinical Trial Opportunity: Phase 3 Study for Wet AMD appeared first on Macular Degeneration Association.